Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Subbiah, V; Shen, T; Terzyan, SS; Liu, X; Hu, X; Patel, KP; Hu, M; Cabanillas, M; Behrang, A; Meric-Bernstam, F; Vo, PTT; Mooers, BHM; Wu, J

Subbiah, V (corresponding author), UT MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 455, Houston, TX 77030 USA.; Mooers, BHM; Wu, J (corresponding author), Univ Oklahoma, Hlth Sci Ctr, 975 NE 10th St,BRC466, Oklahoma City, OK 73104 USA.

ANNALS OF ONCOLOGY, 2021; 32 (2): 261

Abstract

Background: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索